2023
Economic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder
Flam-Ross J, Marsh E, Weitz M, Savinkina A, Schackman B, Wang J, Madushani R, Morgan J, Barocas J, Walley A, Chrysanthopoulou S, Linas B, Assoumou S. Economic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder. JAMA Network Open 2023, 6: e2329583. PMID: 37703018, PMCID: PMC10500382, DOI: 10.1001/jamanetworkopen.2023.29583.Peer-Reviewed Original ResearchConceptsExtended-release buprenorphineIncremental cost-effectiveness ratioMedication treatmentHealth care utilization costsTreatment of OUDOpioid agonist treatmentOpioid use disorderMean lifetime costsCost-effectiveness ratioProbabilistic sensitivity analysesEconomic evaluationCohort studyAgonist treatmentTreatment optionsClinical trialsClosed cohortMAIN OUTCOMEBuprenorphineSimulated cohortUse disordersDrug AdministrationUS FoodPharmaceutical costsQALY willingnessInjectable formEstimated Clinical Outcomes and Cost-effectiveness Associated With Provision of Addiction Treatment in US Primary Care Clinics
Jawa R, Tin Y, Nall S, Calcaterra S, Savinkina A, Marks L, Kimmel S, Linas B, Barocas J. Estimated Clinical Outcomes and Cost-effectiveness Associated With Provision of Addiction Treatment in US Primary Care Clinics. JAMA Network Open 2023, 6: e237888. PMID: 37043198, PMCID: PMC10098970, DOI: 10.1001/jamanetworkopen.2023.7888.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioPrimary care practitionersClinical outcomesPCP servicesPrimary careAddiction servicesAddiction careUS primary care clinicsLong-term clinical outcomesHealth care sector costsInjection-related infectionsPrimary care clinicsHealth care sector perspectivePrimary care practicesCost-effectiveness ratioObservational cohortBuprenorphine prescribingCare clinicsClinical trialsPCP practicesTreatment strategiesMAIN OUTCOMESimulated cohortCare practitionersCare practicesEstimated Costs and Outcomes Associated With Use and Nonuse of Medications for Opioid Use Disorder During Incarceration and at Release in Massachusetts
Chatterjee A, Weitz M, Savinkina A, Macmadu A, Madushani R, Potee R, Ryan D, Murphy S, Walley A, Linas B. Estimated Costs and Outcomes Associated With Use and Nonuse of Medications for Opioid Use Disorder During Incarceration and at Release in Massachusetts. JAMA Network Open 2023, 6: e237036. PMID: 37058306, PMCID: PMC10105308, DOI: 10.1001/jamanetworkopen.2023.7036.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioIncremental costCost-effectiveness ratioEconomic evaluationEconomic studiesOpioid use disorderXR-naltrexoneOverdose deathsTreatment startQALYOverdose mortalityUse disordersCostExtended-release naltrexoneTreatment costsDiscontinue medicationsMOUD accessQALYsOpen cohortMost prisonsIncarcerated individualsMOUD treatmentTreatment strategiesMoneyFatal overdoses
2022
Population‐level impact of initiating pharmacotherapy and linking to care people with opioid use disorder at inpatient medically managed withdrawal programs: an effectiveness and cost‐effectiveness analysis
Savinkina A, Madushani RWMA, Yazdi G, Wang J, Barocas JA, Morgan JR, Assoumou SA, Walley AY, Linas BP, Murphy SM. Population‐level impact of initiating pharmacotherapy and linking to care people with opioid use disorder at inpatient medically managed withdrawal programs: an effectiveness and cost‐effectiveness analysis. Addiction 2022, 117: 2450-2461. PMID: 35315162, PMCID: PMC9377514, DOI: 10.1111/add.15879.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioOpioid use disorderStandard of careUse disordersFatal overdosesDetox patientsMOUD initiationWithdrawal programInitiation of medicationHealth care sector perspectiveRisk of overdoseFatal opioid overdosesCost-effectiveness ratioCost-effectiveness analysisOpioid useHealth care spendingOutpatient careDetox programsOpioid overdosesMOUDPatientsOverdosesPopulation-level impactDisorder populationHealth effectsSimulated Cost-effectiveness and Long-term Clinical Outcomes of Addiction Care and Antibiotic Therapy Strategies for Patients With Injection Drug Use–Associated Infective Endocarditis
Adams JW, Savinkina A, Hudspeth JC, Gai MJ, Jawa R, Marks LR, Linas BP, Hill A, Flood J, Kimmel S, Barocas JA. Simulated Cost-effectiveness and Long-term Clinical Outcomes of Addiction Care and Antibiotic Therapy Strategies for Patients With Injection Drug Use–Associated Infective Endocarditis. JAMA Network Open 2022, 5: e220541. PMID: 35226078, PMCID: PMC8886538, DOI: 10.1001/jamanetworkopen.2022.0541.Peer-Reviewed Original ResearchConceptsOutpatient parenteral antimicrobial therapyIncremental cost-effectiveness ratioOral antibiotic therapyInjection drug use-associated infective endocarditisUsual care strategyAntibiotic therapyOpioid drug useAntibiotic treatment strategiesAntibiotic strategiesCare servicesTreatment strategiesCare strategiesTreatment discontinuationClinical outcomesInfective endocarditisDrug use-associated infective endocarditisDrug useInpatient intravenous antibiotic therapyLong-term clinical outcomesHigher treatment completion rateIntravenous antibiotic therapyObservational cohort studyPercentage of patientsPostacute care facilityParenteral antimicrobial therapy
2021
Clinical impact, costs, and cost-effectiveness of hospital-based strategies for addressing the US opioid epidemic: a modelling study
Barocas JA, Savinkina A, Adams J, Jawa R, Weinstein ZM, Samet JH, Linas BP. Clinical impact, costs, and cost-effectiveness of hospital-based strategies for addressing the US opioid epidemic: a modelling study. The Lancet Public Health 2021, 7: e56-e64. PMID: 34861189, PMCID: PMC8756295, DOI: 10.1016/s2468-2667(21)00248-6.Peer-Reviewed Original ResearchConceptsOpioid use disorderAddiction consult serviceHospital-based strategiesUS opioid epidemicOpioid epidemicUse disordersConsult serviceProbabilistic sensitivity analysesClinical impactDrug useIncremental cost-effectiveness ratioInjection-related infectionsInjection drug useMean lifetime costsNational InstituteCost-effectiveness ratioHarm reduction servicesDeterministic sensitivity analysesInpatient prescribingObservational cohortRecurrent infectionsOutpatient treatmentClinical trialsOverdose riskMedications